Login
Manage Portfolio
Post a StockTalk
Write an Instablog
Get Daily Email Alert
Seeking Alpha
Home
The Macro View
Stocks & Sectors
Global Markets
ETFs
Investing Ideas
Breaking News
Transcripts
Business Intelligence
Dendreon (DNDN)
(
)
Quotes
Dashboard
Chart
Historical Prices
Options
Analysis
Articles
Instablogs
StockTalks
Sentiment
Comments
2 new
News & PR
Market Currents
Buzz
Twitter: DNDN
Coverage
Top Authors
Cramer
Top Analysts
Business Intelligence
Transcripts
Events
Key Developments
Earnings
History & Projected
Consensus
Peer Earnings
Filings
SEC Filings
Annual Report
Ownership
Major Holders
Insider Trades
Insider Sentiment
Index Membership
Short Interest
Financials
Income Statement
Balance Sheet
Cash Flow
Company
Wikipedia Profile
Officers & Directors
Executive Comp
Analysis - Latest Articles
by
most recent
|
most commented
Mentor Capital Cancer Vaccine Investing Update
Dec 23
•
Mike Havrilla
•
2 Comments
30 High Yielding Option Write Ideas for November Option Expiration Friday
Nov 20
•
Marco Hickey
•
1 Comment
Best Performing Stocks Since 3/9/09 and 10/9/07
Nov 12
•
Bespoke Investment Group
•
Comment!
Monday's Rx-Recap (11-02-09)
Nov 3
•
M. E. Garza
•
Comment!
Dendreon's Provenge Looks Likely to Be Approved in Mid-2010
Nov 3
•
VFC's Stock House
•
8 Comments
25 Option Write Ideas for October's Expiration Friday
Oct 16
•
Marco Hickey
•
1 Comment
25 High-Yielding Buy-Writes for October Options Expiration
Oct 14
•
Marco Hickey
•
3 Comments
Dendreon: New Board Members Appointed, Things Have Never Looked Brighter
Oct 12
•
VFC's Stock House
•
5 Comments
Stock Watch: BDSI, ACTC.PK, ONTY
Oct 11
•
VFC's Stock House
•
8 Comments
OncoGenex: Room for Further Growth?
Oct 8
•
EP Vantage
•
Comment!
Stock Watch: CPST, CVM, AGEN
Oct 6
•
VFC's Stock House
•
3 Comments
The Top 25
Oct 1
•
Bespoke Investment Group
•
1 Comment
Dendreon Investors Counting on FDA Approval of Provenge
Sep 28
•
Zacks.com
•
4 Comments
BioMed News Bytes: Dendreon, Chelsea, Cytori, Cephalon, OraSure, Genzyme, Lixte
Sep 25
•
Mike Havrilla
•
3 Comments
Still a Lot of Potential in Dendreon and the Cancer Immunotherapy Market
Sep 25
•
VFC's Stock House
•
7 Comments
Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers
Sep 20
•
Justin M. Hall
•
3 Comments
SEC Shouldn't Rest on Flash Trading Ban
Sep 18
•
Matthew Goldstein
•
12 Comments
Tuesday Options Recap
Sep 15
•
Frederic Ruffy
•
2 Comments
50 Four-Day September Expiration Option Ideas
Sep 15
•
Marco Hickey
•
6 Comments
Monday's Options Recap
Sep 14
•
Frederic Ruffy
•
Comment!
Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up
Sep 11
•
Justin M. Hall
•
23 Comments
Tuesday Options Recap
Aug 25
•
Frederic Ruffy
•
Comment!
3 Reasons Not to Predict FDA Action: Matrixx, Savient, Dendreon
Aug 19
•
Ruthanne Williams Roussel
•
5 Comments
Market Falters but Sentiment Doesn't
Aug 18
•
First Coverage
•
1 Comment
As Market Drops, It's Time to Buy
Aug 18
•
VFC's Stock House
•
12 Comments
Stock Watch: TTNP, VNDA, DNDN, AGEN, ONTY
Aug 17
•
VFC's Stock House
•
3 Comments
Tracking Healthcare Trends and More
Aug 5
•
Mike Havrilla
•
3 Comments
Small Biopharma Ponderings
Jul 27
•
VFC's Stock House
•
Comment!
Expected Volatility: 20 Option Straddle Ideas for High Beta Stocks
Jul 20
•
Marco Hickey
•
5 Comments
10 Stocks to Watch on July Options Expiration Friday
Jul 17
•
Marco Hickey
•
2 Comments
Russell 3,000 Stocks Up More than 200% Year to Date
Jun 28
•
Bespoke Investment Group
•
3 Comments
Russell Indexing Reshuffle Moves Healthcare Stocks: CXM, CTIC, HEB, CPD
Jun 26
•
M. E. Garza
•
Comment!
A Healthy Dose of Funding for Pharma, Biotech
Jun 21
•
The Burrill Report
•
Comment!
Molecular Insight Pharmaceuticals: Two Promising Candidates to Battle Prostate Cancer
Jun 19
•
Michael Becker
•
6 Comments
Best Performing Stocks of the Last Quarter
Jun 15
•
TraderMark
•
4 Comments
Dendreon: Charting the Course to Big Profits
Jun 10
•
Beacon Asset Managers
•
15 Comments
Biotech Opportunities: Look for Decent Pipeline, Big Pharma Partnerships
Jun 2
•
Zacks.com
•
15 Comments
Biotech Stocks and the ASCO-Effect
Jun 1
•
Michael Becker
•
2 Comments
Russell 3000 Stocks Up 200% or More Year to Date
May 29
•
Bespoke Investment Group
•
2 Comments
Access Pharma: A Smallcap Cancer Biotech Call Option Trade
May 28
•
Mike Havrilla
•
13 Comments
A Biotech Triple Play: Dendreon, BioCryst and Arena
May 25
•
Michael Murphy
•
28 Comments
1
2
3
4
5
Next Page